This article is more than 5 years old. Information may no longer be current.

BONESUPPORT extends US distribution agreement for bone void filler with Zimmer Biomet

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BONESUPPORT AB announced it has extended the U.S. distribution agreement for its Cerament bone void filler with Zimmer Biomet.

According to a company press release, the extended agreement grants Zimmer Biomet exclusive rights to distribute the line of bone void filler products for orthopedics, trauma, and foot and ankle applications in the United States (U.S.). BONESUPPORT is also running an FDA-approved investigational device exemption randomized, control pivotal study for its Cerament G, an antibiotic-eluting product that has already been approved in the European Union and other foreign markets.

“We are pleased to extend our distribution agreement with Zimmer Biomet,” Richard Davies, chief executive officer of BONESUPPORT, said in the press release. “The partnership has been successful and has resulted in the current rapid growth of our flagship product, Cerament, in the world’s largest bone graft substitute market. This rapid growth is building an important platform from which we can launch product extensions into the U.S.”

Reference:

www.bonesupport.com